Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

MaskMaker Mar. 20 at 8:53 PM

$APCX $IGC $MPU $NXL $VTGN

0 · Reply

IGC Mar. 20 at 8:19 PM

$IGC Today at AD/PD - Advances in Science & Therapy 2026, the IGC Pharma AI team presented aha™ (Agentic Harmonization Assistant) at the Alzheimer's Disease Data Initiative (ADDI) booth. aha™ is designed to address one of the core challenges in Alzheimer’s research: integrating fragmented datasets across institutions and modalities. By harmonizing tabular and neuroimaging data, it supports cross-cohort analysis and AI-ready research at scale. We are proud to collaborate with ADDI, reflecting a shared commitment to scalable, interoperable data solutions for the global research community. aha™ was recently recognized as a semifinalist in the Alzheimer’s Insights AI Prize, a global initiative by ADDI to accelerate AI-driven discovery. Strengthening research infrastructure is essential to advancing Alzheimer’s science. . . . #ADPD2026 #AlzheimersResearch #AIinHealthcare #IGCPharma

0 · Reply

MaskMaker Mar. 19 at 9:33 AM

$APCX $NXL $MPU $VTGN $IGC Alzheimer’s Disease Prevention starts Here

0 · Reply

Scatchtape Mar. 18 at 7:45 AM

$IGC IGC Pharma’s Feb 26th PR clearly stated they’d present the AHA roadmap at AD/PD 2026. Day 2 has started and I see nothing. No booth, no abstract, no session. What’s the deal? Why are they even there if they’re not on the list?

0 · Reply

AlertsAndNews Mar. 16 at 8:11 PM

$YCBD $AKAN $IGC all getting volume on this FDA Sends CBD Compliance and Enforcement Policy for White House Review

0 · Reply

MarioAndretti Mar. 13 at 10:49 PM

$BHAT I’ve been trading since the early 2000s I mostly have my money in Index funds. I barely play with Penny stocks but I did buy into $LFMD feb 5th. As I saw a great opportunity. Bhat is an obvious scam I tried to tell everyone about $IGC another scam. These stocks are obvious they often change names when people catch on. Take a little of what a bear might say on any ticker!

2 · Reply

CarlSpagler Mar. 12 at 2:02 PM

$IGC covered all my short calls .50 for May. Want my whole position untethered. Made a couple hundred bucks.

0 · Reply

bongha Mar. 4 at 4:17 PM

$IGC when..

0 · Reply

OffComesTheShirt Mar. 4 at 3:34 PM

$IGC 10% Off Comes The Shirt.

0 · Reply

Honeybear89 Mar. 4 at 1:03 PM

$IGC here we go!!

1 · Reply

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

Mar 18, 2026, 9:00 AM EDT - 3 days ago

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

Feb 26, 2026, 8:30 AM EST - 23 days ago

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

Feb 24, 2026, 8:30 AM EST - 25 days ago

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

Feb 23, 2026, 8:30 AM EST - 26 days ago

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

Feb 17, 2026, 8:30 AM EST - 4 weeks ago

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

Feb 12, 2026, 8:30 AM EST - 5 weeks ago

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

Feb 10, 2026, 8:30 AM EST - 5 weeks ago

IGC Pharma Announces Equity Research Update by Alliance Global Partners

Feb 9, 2026, 8:30 AM EST - 5 weeks ago

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

Feb 2, 2026, 8:30 AM EST - 6 weeks ago

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

Jan 22, 2026, 9:00 AM EST - 2 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

Jan 12, 2026, 9:00 AM EST - 2 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

Jan 6, 2026, 8:00 AM EST - 2 months ago

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

Jan 5, 2026, 9:00 AM EST - 2 months ago

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

Dec 19, 2025, 9:00 AM EST - 3 months ago

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

Dec 15, 2025, 9:00 AM EST - 3 months ago

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

Dec 10, 2025, 9:00 AM EST - 3 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

Dec 9, 2025, 9:00 AM EST - 3 months ago

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Dec 2, 2025, 9:00 AM EST - 3 months ago

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Nov 25, 2025, 9:00 AM EST - 4 months ago

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov 17, 2025, 8:30 AM EST - 4 months ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov 13, 2025, 9:00 AM EST - 4 months ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov 10, 2025, 9:00 AM EST - 4 months ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov 3, 2025, 8:52 AM EST - 4 months ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Oct 22, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 14, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 10, 2025, 7:50 PM EDT - 5 months ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 7, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Sep 29, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 24, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 22, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 9, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 2, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Aug 28, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

Aug 27, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

Aug 25, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

Aug 19, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Aug 12, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

Aug 5, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

Jul 23, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

Jul 21, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

Jul 10, 2025, 3:10 PM EDT - 9 months ago

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

Jun 30, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 27, 2025, 8:30 AM EDT - 9 months ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

Jun 23, 2025, 8:30 AM EDT - 9 months ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

May 22, 2025, 9:30 AM EDT - 10 months ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

May 12, 2025, 9:30 AM EDT - 11 months ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

Apr 24, 2025, 9:30 AM EDT - 11 months ago

IGC Pharma Welcomes Strategic Investment from Advisors

Apr 21, 2025, 9:30 AM EDT - 11 months ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Apr 8, 2025, 9:30 AM EDT - 1 year ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

MaskMaker Mar. 20 at 8:53 PM

$APCX $IGC $MPU $NXL $VTGN

0 · Reply

IGC Mar. 20 at 8:19 PM

0 · Reply

MaskMaker Mar. 19 at 9:33 AM

$APCX $NXL $MPU $VTGN $IGC Alzheimer’s Disease Prevention starts Here

0 · Reply

Scatchtape Mar. 18 at 7:45 AM

0 · Reply

AlertsAndNews Mar. 16 at 8:11 PM

$YCBD $AKAN $IGC all getting volume on this FDA Sends CBD Compliance and Enforcement Policy for White House Review

0 · Reply

MarioAndretti Mar. 13 at 10:49 PM

2 · Reply

CarlSpagler Mar. 12 at 2:02 PM

$IGC covered all my short calls .50 for May. Want my whole position untethered. Made a couple hundred bucks.

0 · Reply

bongha Mar. 4 at 4:17 PM

$IGC when..

0 · Reply

OffComesTheShirt Mar. 4 at 3:34 PM

$IGC 10% Off Comes The Shirt.

0 · Reply

Honeybear89 Mar. 4 at 1:03 PM

$IGC here we go!!

1 · Reply

RocketQueen Feb. 28 at 12:11 AM

$IGC when is full patient enrollment?

0 · Reply

IGC Feb. 27 at 3:57 PM

$IGC Utility patent applications have been filed to protect key elements of IGC Pharma’s Agentic Harmonization Assistant (AHA), which is being designed as a structured, multi-stage architecture intended to automate dataset alignment and validation across diverse Alzheimer’s datasets. Earlier this year, AHA advanced to the semi-final round of a competitive AI research evaluation program. The Company plans to present additional details regarding AHA’s development roadmap at the upcoming ADPD conference. Read the full press release: https://shorturl.at/aSUbG . . . #ArtificialIntelligence #AlzheimersResearch #DataHarmonization #IGCPharma

0 · Reply

distanceswimmer Feb. 26 at 4:25 PM

$IGC buy some, see if they show up, bought 170 shares, never displayed

0 · Reply

QuantumWizard Feb. 25 at 11:48 PM

$IGC It seems 2026 is the last operational milestone for all of us to see if this Stock is a Win or Bust

1 · Reply

BearLifeWithShorts Feb. 25 at 11:14 PM

$IGC https://www.investorbust.com/post/igc-pharma-stock-stabilizes-near-52-week-lows-as-phase-2-alzheimer-s-trial-catalyst-approaches

0 · Reply

IGC Feb. 24 at 2:21 PM

$IGC Ascendiant Capital Markets has issued an updated equity research report covering IGC Pharma Statements, opinions, and conclusions in analyst reports reflect the views of the respective analysts and not those of IGC Pharma, which does not endorse or guarantee the accuracy or completeness of such reports. Read the full report: https://ascendiant.com/research-reports/igc-q3-fy26/

0 · Reply

RocketQueen Feb. 24 at 1:17 AM

$IGC did anyone listen in on the fireside chat?

0 · Reply

prismmarketview Feb. 23 at 4:08 PM

We’ve added IGC Pharma (NYSE: $IGC) to the PRISM Pharmaceuticals Index. IGC Pharma is advancing IGC-AD1 in its Phase 2 CALMA trial for agitation in Alzheimer’s dementia, with over 70% enrollment complete and trial completion expected in the first half of 2026. With interim data showing a statistically significant reduction in agitation and key milestones ahead, IGC is a clinical-stage name to watch in 2026. https://prismmarketview.com/companies/igc-pharma-inc/

0 · Reply

erevnon Feb. 23 at 11:25 AM

Ascendiant Capital maintains IGC Pharma $IGC at Buy and raises the price target from $4.75 to https://marketsblock.com/stock-upgrades-and-downgrades/

1 · Reply

FoxyDreams Feb. 20 at 12:11 PM

$IGC valuation depends almost entirely on the success of one clinical asset. If this drug fails in clinical trials a common outcome in Alzheimer’s research and the company has no diversified pipeline to fall back on, magnifying risk.

0 · Reply

CarlSpagler Feb. 19 at 6:54 PM

$IGC still holding 61k

0 · Reply

dwiz5 Feb. 18 at 9:59 PM

$IGC bought more total 65K worth. G/L

0 · Reply

Market Cap	26.18M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-560.63%
Debt to Equity Ratio	0.02

Volume	766,100
Avg Vol	370,936
Day's Range	N/A - N/A
Shares Out	95.04M
Stochastic %K	65%
Beta	0.31
Analysts	Sell
Price Target	$4.00